<SEC-DOCUMENT>0001564590-21-045817.txt : 20210826
<SEC-HEADER>0001564590-21-045817.hdr.sgml : 20210826
<ACCEPTANCE-DATETIME>20210826085821
ACCESSION NUMBER:		0001564590-21-045817
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20210826
FILED AS OF DATE:		20210826
DATE AS OF CHANGE:		20210826

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		211208963

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190847081

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>bntx-6k_20210826.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-6k_20210826.DOCX.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:20pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549<font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:20pt;"><br /></font><font style="font-weight:bold;color:#000000;font-size:20pt;">FORM 6-K</font><font style="color:#000000;font-size:20pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a&#8209;16 OR 15d&#8209;16<font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNDER THE SECURITIES EXCHANGE ACT OF 1934<font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOR THE MONTH OF AUGUST 2021<font style="font-weight:normal;color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COMMISSION FILE NUMBER 001-39081 </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE<br /><font style="color:#333333;font-size:10pt;font-weight:normal;">(Translation of registrant&#8217;s name into English)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">An der Goldgrube 12</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">D-55131 Mainz</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Germany</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">+49 6131-9084-0<br /><font style="color:#333333;font-size:10pt;font-weight:normal;">(Address of principal executive offices)</font><font style="font-weight:normal;color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20&#8209;F or Form 40&#8209;F:<font style="color:#000000;"> </font>Form 20&#8209;F <font style="font-family:Segoe UI Symbol;">&#9746;</font> Form 40&#8209;F <font style="font-family:Segoe UI Symbol;">&#9744;</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(1):<font style="color:#000000;"> </font><font style="font-family:Segoe UI Symbol;">&#9744;</font> </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(7)<font style="color:#000000;">: </font><font style="font-family:Segoe UI Symbol;">&#9744;</font> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;">DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk80355245"></a>On August 26, 2021, BioNTech SE (the &#8220;Company&#8221;) and Pfizer Inc. today announced the signing of a letter of intent with Eurofarma Laborat&#243;rios SA<a name="_Hlk80355245"></a>, a Brazilian biopharmaceutical company, to manufacture COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (COVID-19 vaccine, mRNA) (BNT162b2) for distribution within Latin America. The press release is attached hereto as Exhibit 99.1.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;">SIGNATURE</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<font style="color:#000000;"> </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.63%;"></td>
<td style="width:4.63%;"></td>
<td style="width:44.73%;"></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Dr. Sierk Poetting</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Dr. Sierk Poetting</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp; Chief Operating Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 26, 2021 </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;">EXHIBIT INDEX </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:10.98%;"></td>
<td style="width:89.02%;"></td>
</tr>
<tr style="height:1pt;">
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit</font></p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Description of Exhibit</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:22.5pt;">
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex991_6.htm"><font style="text-decoration:underline;">Pfizer and BioNTech Announce Collaboration with Brazil&#8217;s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>bntx-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.66%;"></td>
<td style="width:49.34%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpbisf2hhsz0000001.jpg" title="" alt="" style="width:240px;height:26px;"></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gpbisf2hhsz0000002.jpg" title="" alt="" style="width:153px;height:62px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.72%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Pfizer and BioNTech Announce Collaboration with Brazil&#8217;s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk80859419"></a><a name="_Hlk80355245"></a>NEW YORK, USA and MAINZ, GERMANY, August 23, 2021 <font style="font-weight:normal;">&#8212; </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Pfizer Inc.</font><font style="font-weight:normal;"> (NYSE: PFE) and </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">BioNTech SE</font><font style="font-weight:normal;"><a name="_Hlk80859419"></a> (Nasdaq: BNTX) </font><font style="font-weight:normal;color:#000000;">today announced the signing of a letter of intent with Eurofarma Laborat&#243;rios SA<a name="_Hlk80355245"></a>, a Brazilian biopharmaceutical company, to manufacture COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (COVID-19 vaccine, mRNA) (BNT162b2) for distribution within Latin America. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eurofarma will perform manufacturing activities within Pfizer&#8217;s and BioNTech&#8217;s global COVID-19 vaccine supply chain and manufacturing network, which will now span four continents and include more than 20 manufacturing facilities. To facilitate Eurofarma&#8217;s involvement in the process, technical transfer, on-site development, and equipment installation activities will begin immediately. Per the agreement, Eurofarma will obtain drug product from facilities in the U.S., and manufacturing of finished doses will commence in 2022. At full operational capacity, the annual production is expected to exceed 100 million finished doses annually. All doses will exclusively be distributed within Latin America.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Everyone &#8211; regardless of financial condition, race, religion or geography &#8211; deserves access to lifesaving COVID-19 vaccines,&#8221; <font style="font-weight:bold;">said Albert Bourla, Chairman and Chief Executive Officer</font>, Pfizer. &#8220;Our new collaboration with Eurofarma expands our global supply chain network to another region &#8211; helping us continue to provide fair and equitable access to our COVID-19 vaccine. We will continue to explore and pursue opportunities such as this to help ensure that vaccines are available to all who are in need.&#8221; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We have been continuously increasing the manufacturing capacity of our own facilities and included dozens of manufacturing partners into our global network. Together with Pfizer, we have delivered more than 1.3 billion doses and we plan to deliver 3 billion doses in total by the end of the year. Today&#8217;s partnership is an important step to broaden the access to vaccines in Latin America and beyond by expanding our global manufacturing network,&#8221; <font style="font-weight:bold;">said Ugur Sahin, M.D., CEO and Co-founder of BioNTech.</font> &#8220;We will continue to enable people worldwide to manufacture and distribute our vaccine while ensuring the quality of the manufacturing process and the doses.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;At such a difficult time as this one, being able to share this news fills us with pride and hope. Eurofarma is about to turn 50 years old and signing this collaboration in the production of the COVID-19 vaccine represents another milestone in our trajectory. We are making available our best resources in terms of industrial capacity, technology and quality to this project, so that we can meet the contract with excellence and contribute to supplying the Latin American market,&#8221; <font style="font-weight:bold;">said Maur&#237;zio Billi, President, Eurofarma.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer and BioNTech select contract manufacturers using a rigorous process based on several factors: quality, compliance, safety track record, technical capability, capacity availability, highly trained workforce, project management abilities, prior working relationship, and commitment to working with flexibility through a fast-paced program.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, Pfizer and BioNTech have shipped more than 1.3 billion COVID-19 vaccine doses to more than 120 countries and territories in every region of the world. The companies are firmly committed to working towards equitable and affordable access for COVID-19 vaccines for all people around the world, actively working with global governments and global health partners with the aim to provide 2 billion doses to low and middle income countries in 2021 and 2022 &#8211; 1 billion each year. This includes direct supply agreements with individual country governments; an agreement to supply 500 million doses to the U.S. Government at a not-for-profit price, which the government will, in turn, donate to the African Union and the COVAX 92 Advanced Market Commitment (AMC) countries; and a direct supply agreement with COVAX for 40 million doses in 2021. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMIRNATY, which is based on BioNTech&#8217;s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union and the United Kingdom, and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer), Canada and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">U.S. Indication &amp; Authorized Use</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (COVID-19 vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.9%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">prevent COVID-19 in individuals 12 through 15 years, and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.9%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pfizer-BioNTech COVID-19 vaccine has received EUA from FDA to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">prevent COVID-19 in individuals 12 years of age and older, and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA-approved COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (COVID-19 vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (COVID-19 vaccine, mRNA) or the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">EUA Statement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Important Safety Information&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individuals should <font style="font-weight:bold;">not</font> get the Pfizer-BioNTech COVID-19 vaccine if they:&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">had a severe allergic reaction after a previous dose of this vaccine&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">had a severe allergic reaction to any ingredient of this vaccine&#160;&#160;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individuals should tell the vaccination provider about&#160;all of their medical conditions, including if they:&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">have any allergies&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">have a fever&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">have a bleeding disorder or are on a blood thinner&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">are immunocompromised or are on a medicine that affects the immune system&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">are pregnant, plan to become pregnant, or are breastfeeding&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">have received another COVID-19 vaccine&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">have ever fainted in association with an injection&#160;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The vaccine may not protect everyone.&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Side effects reported with the vaccine include:&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">There is a remote chance that the vaccine could cause a severe allergic reaction&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.9%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the vaccine. For this reason, vaccination providers may ask individuals to stay at the place where they received the vaccine for monitoring after vaccination&#160;</font></p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.9%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:Courier New;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">Signs of a severe allergic reaction can include difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, dizziness, and weakness&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.9%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">If an individual experiences a severe allergic reaction, they should call 9-1-1 or go to the nearest hospital&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:&#160;&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.9%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">chest&#160;pain&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.9%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">shortness of&#160;breath&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.9%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">feelings of having a fast-beating, fluttering, or pounding heart&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">Side effects that have been reported with the vaccine include:&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.9%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">severe allergic reactions; non-severe allergic reactions such as rash, itching, hives, or swelling of the face; myocarditis (inflammation of the heart muscle); pericarditis (inflammation of the lining outside the heart); injection site pain; tiredness; headache; muscle pain; chills; joint pain; fever; injection site swelling; injection site redness; nausea; feeling unwell; swollen lymph nodes (lymphadenopathy); diarrhea; vomiting; arm pain&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.97%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Arial;color:#000000;">These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away&#160;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no information on the use of the vaccine with other vaccines.&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1<font style="font-family:Cambria Math;">&#8208;</font>800<font style="font-family:Cambria Math;">&#8208;</font>822<font style="font-family:Cambria Math;">&#8208;</font>7967.&#160;In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please <font style="text-decoration:underline;">click here</font> for full Prescribing Information (16+ years of age). Please <font style="text-decoration:underline;">click here</font> for Fact Sheet for Vaccination Providers (12+ years of age).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About Pfizer: Breakthroughs That Change Patients&#8217; Lives</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <font style="text-decoration:underline;">www.Pfizer.com</font>. In addition, to learn more, please visit us on <font style="text-decoration:underline;">www.Pfizer.com</font> and follow us on Twitter at <font style="text-decoration:underline;">@Pfizer</font> and <font style="text-decoration:underline;">@Pfizer News</font>, <font style="text-decoration:underline;">LinkedIn</font>, <font style="text-decoration:underline;">YouTube</font> and like us on Facebook at <font style="text-decoration:underline;">Facebook.com/Pfizer</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Disclosure Notice </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk54352787"></a>The information contained in this release is as of August 26, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64379077"></a>This release contains forward-looking information about Pfizer&#8217;s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the collaboration between BioNTech, Pfizer and Eurofarma to manufacture and distribute COVID-19 vaccine doses within Latin America, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including qualitative assessments of available data, potential benefits, expectations for clinical trials, supply agreements and the timing of delivery of doses thereunder, efforts to help ensure global equitable access to the vaccine,&#160;the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unfavorable</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when the submission of the supplemental Biologics License Application (</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sBLA</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) for a potential booster (third) dose in the U.S. will be completed and accepted for review, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sBLA</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine&#8217;s benefits outweigh its known risks and determination of the vaccine&#8217;s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">labeling</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine&#8217;s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer&#8217;s business, operations and financial results; and competitive developments.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A further description of risks and uncertainties can be found in Pfizer&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221;, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at&#160;<font style="text-decoration:underline;">www.sec.gov&#160;</font>and&#160;<font style="text-decoration:underline;">www.pfizer.com</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About BioNTech </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genevant</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fosun</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Pharma, and Pfizer. For more information, please visit </font><font style="text-decoration:underline;">www.BioNTech.de</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Forward-looking Statements </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains &#8220;forward-looking statements&#8221; of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech&#8217;s efforts to combat COVID-19; the collaboration between BioNTech, Pfizer and Eurofarma to manufacture and distribute COVID-19 vaccine doses within Latin America; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including the approval of the BLA for BNT162b2 to prevent COVID-19 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of BNT162b2 in individuals 16 years of age and older and/or a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence, a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a discussion of these and other risks and uncertainties, see BioNTech&#8217;s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC&#8217;s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Contacts:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media Relations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amy Rose</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+1 (212) 733-7410</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Amy.Rose@pfizer.com</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chuck Triano</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+1 (212) 733-3901</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Charles.E.Triano@Pfizer.com</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Contacts:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media Relations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jasmina Alatovic</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+49 (0)6131 9084 1513 </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Media@biontech.de</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sylke Maas, Ph.D.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+49 (0)6131 9084 1074</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Investors@biontech.de</font> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gpbisf2hhsz0000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpbisf2hhsz0000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $M"JD# 2(  A$! Q$!_\0
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MT:/M$W_/:3_OHU'10%V2?:)O^>TG_?1H^T3?\]I/^^C4=% 79)]HF_Y[2?\
M?1H^T3?\]I/^^C4=% 79)]HF_P">TG_?1H^T3?\ /:3_ +Z-1T4!=DGVB;_G
MM)_WT:/M$W_/:3_OHU'10%V2?:)O^>TG_?1H^T3?\]I/^^C4=% 79)]HF_Y[
M2?\ ?1H^T3?\]I/^^C4=% 79)]HF_P">TG_?1H^T3?\ /:3_ +Z-1T4!=DRW
M=RAREQ*I]G(JS%K>K0?ZK4[Q,=A.V/YU0HH&I-;,Z"W\;>(+8\:@TB^DJ*WZ
MXS6Y9?$Z[0@7MA#*O]Z%BA_(YK@Z*9K'$58[2/9=-\<:'J)"&X-M(?X+@;?U
MZ?K71 AE#*001D$=Z^>*U=)\1ZIHKC[)<MY6>87^9#^';\,47.NGCWM-'N=%
M<KH'CFPU<K;W(%I=G@*S?(Y]CZ^Q_6NJIGHPJ1FKQ84444%A1110 4444 %%
M%% !7"_$UW33K$HS+F9NAQVKNJX3XG_\@VP_Z[-_*AG/BOX,CS;[1-_SVD_[
MZ-'VB;_GM)_WT:CHJ3PKLD^T3?\ /:3_ +Z-'VB;_GM)_P!]&HZ* NR3[1-_
MSVD_[Z->M_#YF?PJA9BQ\Y^2<]Z\@KUWX>?\BI'_ -=G_G31VX!_O?D=7111
M3/8"BBB@ HHHH **** "BBB@ HHHH **** "BBD9E12S$*H&22>!0 M%<UJ?
MCK1-.W(DYNI1_# -P_[ZZ5R&H?$G4[@E;*"&T3LQ'F-^O'Z47.>IBJ4-V>J$
M@#). *RKOQ)HMCD7&I6X8=55M[?DN37C-[J^HZB3]LO9Y@?X6<[?RZ52I7.2
M>8/[,3U>Z^)&C0\01W-P?54"C]3G]*R+CXH3'(MM,1?0R2EOT %>?T47.>6-
MK/K8ZV;XC:[+G9]EA_W(L_S)JC+XT\0S?>U)Q_N(J_R%8%%(R=>J]Y,TW\1Z
MW(<G5KT?[L[#^1JNVJ:@XP]_=,/>9C_6JE%!#G)[LG>\NI,;[F9L=,N33/M$
MW_/:3_OHU'103=DGVB;_ )[2?]]&C[1-_P ]I/\ OHU'10%V2?:)O^>TG_?1
MJ07]X.EW.,?]-#5>B@=V7UUO5D.4U.]4^UPX_K5B/Q3KL7W=5N3_ +S[OYUD
M44#52:V9TD7CSQ%%UO5D'H\*?T%:,'Q,U9.)K6TD'LK*?Y_TKBJ*9HL156TF
M>E6WQ0MVP+K394]3%(&_0@5LVOCS0+K :Z>!CVFC(_49'ZUXY11<VCCJJWU/
MH"UO[.]7=:W4,X_Z9R!OY58KYX5V1PZ,58<@@X(K<L/&.NZ>0$OGE0?P3_.#
M^)Y_(T7.B&8+[2/:Z*\_TWXFQ,534K(H>\D!R/\ OD_XFNQTW6]-U9-UC>1R
MG&2@.&'U4\TSLIUZ=3X67Z***#4**** "BBB@ HHHH **** "BBB@ HHHH *
M*** .3\3LRZE& Q'[D=#[M6+YC_WV_.MGQ1_R$X_^N(_FU8E?%9@W]:GZFBV
M'>8_]]OSH\Q_[[?G3:*XKL!WF/\ WV_.CS'_ +[?G3:*+L"_INK3Z?-G)>)O
MO(3U]Q[UV=K=0WD"S0MN4_F#Z&O/:M6%_-I\_F1'@_>4]&%>KE^92P[Y)ZQ_
M(35SOJ*JV-_#J$'F1-R/O*>JFK5?5PG&<5*+NF0%%%%4 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>=R2/
MYC?.W4]Z]$KSF3_6-]37S^>MI4_G^A40\Q_[[?G1YC_WV_.FT5\[=E#O,?\
MOM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_
M.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\
MOM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_
M.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\
MOM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_
M.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\
MOM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_
M.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\
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MT:/M$W_/:3_OHU'10%V2?:)O^>TG_?1H^T3?\]I/^^C4=% 79)]HF_Y[2?\
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MY5E."#3N==+&5(:/5'T-17FGAWXA2P;+;6<RQ]!<J/F7_>'?Z]?K7H\$\5S
MD\$BR1.,JZG((IGJTJT*JO$DHHHH-0HHHH **** "BBB@ HHHH **** .2\4
M?\A./_KB/YM6)6WXH_Y"<?\ UQ'\VK$KXG,?]ZGZFBV"BBBN( HHHH ****
M)[6[FLIUFA;:PZCL1Z&NSTW5(=1ARORRJ/G0]OI[5PM20S26\JRQ.4=3D$5Z
M&!Q\\+*V\>W^0FKGHE%9FDZQ'J";'PEP!RO][W%:=?7T:T*T%.#NB HHHK0
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KSF3_6-]37HU><R?ZQOJ:^?S[:G\_P!"HC:***^<*"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\9\=?\
M(Y7_ /VS_P#1:U[-7C/CK_D<K_\ [9_^BUI,X<P_A+U_S.=HHHI'D!1110 5
M[-7C->S4SMP?VOD>.W'_ !\R_P"^?YU'76R_#[7GF=A'!@L2/WHIO_"O-?\
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M_D&V'_79OY4,Y\7_  9'F5%%%2>$%%%% !7KOP\_Y%2/_KL_\Z\BKUWX>?\
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M<UC-Y4P ;&[@YXJO7-*,H2Y9*S0!1114@%%%% !16JGAZ_=%8+'AAD?/3O\
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M^%>:_P#\\[?_ +^B@/J]7^5G*45U?_"O-?\ ^>=O_P!_11_PKS7_ /GG;_\
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M** "O9J\9KV:F=N#^U\CHJ***9[ 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(RJZE7
M4,I&"",@TM% '(:[X!T_45>6P"V=T>0%'[MOJ.WX?D:\PU#3[K2[Q[2\B,<R
M=0>A'J#W%>_5A>*/#L.OZ:R!56[C!,$GH?[I]C_]>E8X<1A(S7-#1GBE%.DC
M>*1HY%*NA*LIZ@CJ*;2/("BBB@ IT;M%(LB,5="&4CL13:* /?\ 3KM;_3;:
M[7I-$KX],CI5FN9\!7)N/"5LI.3"SQG\\C]"*Z:J/HJ<N:"EW"BBB@L****
M"N$^)_\ R#;#_KLW\J[NN$^)_P#R#;#_ *[-_*AG/B_X,CS*BBBI/""BBB@
MKUWX>?\ (J1_]=G_ )UY%7KOP\_Y%2/_ *[/_.FCMP'\7Y'5T444SV HHHH
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MV?$W_(5'_7(?S-8U?$8__>I^IHM@HHHKC **** /0[?_ (]HO]P?RJ6HK?\
MX]HO]P?RJ6OT&'PHS"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBJ&M:K#HNE37TW.P81?[S'H*!-J*NSF_'?B<Z9;?V;9OB[F7]X
MP/,:?XG_ #VKRJI[R[FO[R6[N'WS2L68_P">U04CP:]9U9WZ!1112,0HHHH
M**** "BM?1O#>IZZ_P#HD&(<X::3A!^/?\*]#TCX?:78!9+W-[,.3OX0?\![
M_C3-Z6&J5=4M#S&QTJ_U.3996DLY[E%X'U/05U-A\-=2G :]N8;5?[H_>-^G
M'ZUZA%%'#&L<4:QHHP%08 _"GT6/0A@(+XG<Y"S^'.BP &X:XNF[AGVK^2\_
MK6Y;>'=&L\>1IEJI'1C&&/YGFM.BF=,:-..R$5510JJ%4= !BEHHH-0HHHH
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MT3'YT/?Z>]=G:7<-[ LT+;E/4=P?0U]=@<?#%1MM+M_D0U8GHHHKT!!1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O&?'7_(Y7__ &S_ /1:U[-7C/CK_D<K_P#[9_\
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M]:]6J"RLX=/LH;2W3;#$H51_GO4]4>]0HJE"W4****#8**** "BBB@ HHHH
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MS(:L7Z***]404444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ***9[ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9O<5J5YPCLCAT8JRG((/(KK='UQ;L+;W)"S] W9__KU]/EV:*K:E6^+H^_\
MP26C:HHHKVR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J'4[$'!NX?
M^^Q5NO.9/]8WU->9F..GA%'E5[W&E<[O^U+#_G[A_P"^Q1_:EA_S]P_]]BN"
MHKS/[=J_RHKE.]_M2P_Y^X?^^Q1_:EA_S]P_]]BN"HH_MVK_ "H.4[^/4+.:
M01QW,3NW10W)JS7#Z)_R&;;_ 'C_ "-=Q7KY?BY8JFYR5K.Q+5@HHHKO$%%%
M% !1110 4444 %%%% !1110!R'B;_D*C_KD/YFL:MGQ-_P A4?\ 7(?S-8U?
M$8__ 'J?J:+8****XP"BBB@#T.W_ ./:+_<'\JEJ*W_X]HO]P?RJ6OT&'PHS
M"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZS>?V?HMY=@X
M:*%F7_>QQ^N*O5RGQ#NO(\+-$#S<3)'^ ^;_ -EH,ZLN6FY'D5%%%2?/!111
M0 445K>&=-_M;Q#9VK#,9??)_NKR?SQC\:!QBY-174]1\%Z.-)\/0[UQ<7'[
MZ7/49Z#\!C\<UT-%%4?10@H145T"BBB@H**** "BBB@ HHHH **** "BBB@
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M^T0_\]H_^^A0%T245']HA_Y[1_\ ?0H^T0_\]H_^^A0%T244=1D44#"BBB@
MHHHH *\\^*%Q\NFVP/4O(P_(#^M>AUY7\2Y=WB"WB[); _B6;_ZU#.7&NU%G
M%T445)X@4444 %>@?#&QW3WU^P^XJPH?KR?Y#\Z\_KU_X?6OV?PI%)CF>1Y#
M^>W_ -EIHZ\%'FJKR.IHHHIGM!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !12,RH,LP4>I.*9]HA_Y[1_]]"@+DE%1_:(?^>T?_?0
MH^T0_P#/:/\ [Z% KHDHJ/[1#_SVC_[Z%'VB'_GM'_WT* NB2BH_M$/_ #VC
M_P"^A1]HA_Y[1_\ ?0H"Z)**C^T0_P#/:/\ [Z%'VB'_ )[1_P#?0H"Z)**C
M^T0_\]H_^^A1]HA_Y[1_]]"@+HDHJ/[1#_SVC_[Z%'VB'_GM'_WT* NB2BH_
MM$/_ #VC_P"^A1]HA_Y[1_\ ?0H"Z)**C^T0_P#/:/\ [Z%'VB'_ )[1_P#?
M0H"Z)**C^T0_\]H_^^A1]HA_Y[1_]]"@+HDHJ/[1#_SVC_[Z%'VB'_GM'_WT
M* NB2BH_M$/_ #VC_P"^A1]HA_Y[1_\ ?0H"Z)**C^T0_P#/:/\ [Z%'VB'_
M )[1_P#?0H"Z)**C^T0_\]H_^^A1]HA_Y[1_]]"@+HDHJ/[1#_SVC_[Z%'VB
M'_GM'_WT* NB2BH_M$/_ #VC_P"^A1]HA_Y[1_\ ?0H"Z)**C^T0_P#/:/\
M[Z%'VB'_ )[1_P#?0H"Z)**C^T0_\]H_^^A1]HA_Y[1_]]"@+HDHJ/[1#_SV
MC_[Z%'VB'_GM'_WT* NB2O&?'7_(Y7__ &S_ /1:U[,"",@Y!KQGQU_R.5__
M -L__1:TF<68?PEZ_P"9SM%%%(\@**** "O9J\9KV:F=N#^U\CQVX_X^9?\
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MX0T]<8RC-^;$_P!:WJH^@H*U**\@HHHH-0HHHH **** "BBB@ HHHH ****
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MM(8^?D15YZ\"FCT<O7O29+1113/4"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .4^(?_(J2?\ 79/YUY%7KOQ#_P"14D_Z[)_.O(J3
M/&Q_\7Y!1112.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KV:O&:]FIG;@_M?(\=N/^/F7_?/\ZCJ2X_X^9?]\_SJ.D<3W"BBB@ HHHH
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M]=D_G7D5>N_$/_D5)/\ KLG\Z\BI,\;'_P 7Y!1112.,**** "BBB@ HHHH
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M>?\ (J1_]=G_ )TT=N _B_(ZNBBBF>P%%%% !1110!Y?\3@?[:LVQP;?&?\
M@1KAZ[_XH1XN]-DY^9'7\B/\:X"DSPL6K5I!1112.<**** /:?!,GF^$-/.<
MX5EZ^CL*WZY'X<S^;X8,>>8IW7'UP?ZUUU4?04'>E%^04444&H4444 %%%%
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M ,_-A_W\?_XBC_A6>L_\_-A_W\?_ .(H#ZM6_E.,HKL_^%9ZS_S\V'_?Q_\
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M;^4XRBNS_P"%9ZS_ ,_-A_W\?_XBC_A6>L_\_-A_W\?_ .(H#ZM6_E/3-/\
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M7J_RLY"BNO\ ^%<:Y_?M/^_I_P */^%<:Y_?M/\ OZ?\* ^KU?Y6<A177_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!<1_-JQ*^)S'_>I^IHM@HHHKB **** /0;+_CQM_\ KDO\JGJ"R_X\;?\
MZY+_ "J>OT"G\"]#,****L HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MR-7T5+X&:'"7 _)_K[^]<A)&\4C1R*5=3@@CD5Z-6;JND1:C'N&$G4?*_K['
MVKQ<QRM5KU*6DNW?_@E)G$T5+<6\MK,T,R%77J#45?+M.+L]R@HHHI %%%%
M!6_HVNF';;7;$Q=$D/\ #]?:L"BM\/B*F'GSP8-7/1P0P!!!!&01WI:X_2-;
M>R(AG)>W/3U3Z>WM771R)+&KQL&1AD$=#7V&#QM/%0O'?JB&K#J***[!!7G,
MG^L;ZFO1J\YD_P!8WU-?/Y]M3^?Z%1&T445\X4%%%% &AHG_ "&;;_>/\C7<
M5P^B?\AFV_WC_(UW%?4Y'_ EZ_HB9!1117M$A1110 4444 %%%% !1110 44
M44 <AXF_Y"H_ZY#^9K&K9\3?\A4?]<A_,UC5\1C_ />I^IHM@HHHKC ****
M/0[?_CVB_P!P?RJ6HK?_ (]HO]P?RJ6OT&'PHS"BBBJ **** "BBB@ HHHH
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MZH^AIS4XJ2ZA11106%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!RGQ#_P"14D_Z[)_.O(J]=^(?_(J2?]=D_G7D5)GC8_\ B_(****1QA11
M10!ZC\,O^0)>?]?/_LHKMZXCX9?\@2\_Z^?_ &45V]4>[A?X,0HHHH.@****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWC_(UW%</HG_ "&;;_>/\C7<5]3D?\"7K^B)D%%%%>T2%%%% !1110 4444
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M% !1110 4444 %%%% !1110 4444 %%%% !113)IHK>)I9I$CC499W; 'XT
M/K$\1>)K/P_;9E(EN6'[N!3R?<^@]ZYOQ!\1(HPUOHP\Q^AN77Y1_N@]?J?U
MKSNXN)KNX>>XE:65SEG<Y)I7."OC8Q]VGJR?4]3NM7OGO+R3?(W0=E'8 =A5
M.BBD>4VV[L****!!1110 5VWPXTDW.K2:C(O[NU7:F1U<_X#/YBN+CC>65(X
MU+.[!54=23T%>X^'=(71-%@LQ@R ;I6'\3GK_A] *:.O!4N>IS/9&K1113/:
M"BBB@ HHHH **** .2\4?\A./_KB/YM6)6WXH_Y"<?\ UQ'\VK$KXG,?]ZGZ
MFBV"BBBN( HHHH ]!LO^/&W_ .N2_P JGJ"R_P"/&W_ZY+_*IZ_0*?P+T,PH
MHHJP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (KBWBNH6
MAF0,C=CVKC=4TF73I,\O Q^5_P"A]Z[>F21I-&T<BAD88(/>N#&X"&*CVDMF
M-.QYU16OJ^BO8L9H<O;D_BGL?\:R*^1K4)T9N%16984445B 4444 %6;*^FL
M)Q+"W^\IZ,/>JU%5"<H24HNS0'>Z?J,.HP>9&<,/OH>JFN$D_P!8WU-/MKF6
MTG6:%RKK^M1D[F)/<YKNQF.>*IP4E[RO?\!)6$HHHKSQA1110!H:)_R&;;_>
M/\C7<5P^B?\ (9MO]X_R-=Q7U.1_P)>OZ(F04445[1(4444 %%%% !1110 4
M444 %%%% '(>)O\ D*C_ *Y#^9K&K9\3?\A4?]<A_,UC5\1C_P#>I^IHM@HH
MHKC **** /0[?_CVB_W!_*I:BM_^/:+_ '!_*I:_08?"C,****H HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH QO%6D_VSX?N+9%S,H\R'_>'
M;\1D?C7B%?1%>/>.-$.DZXTT:8MKLF1,= W\0_/G\:3/-Q]*Z51',4444CS
MHHHH **** .[\'^-OL:QZ;JLA, ^6*<\^7[-[>_;Z=/3%97171@RL,A@<@BO
MGBNB\/>,+_02(L_:+//,+G[O^Z>W\J=SOPV,Y?=J;'LU%9.C>(],UR,&TG'F
MXRT+\./P[_49K6IGJQDI*Z"BBB@84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!RGQ#_P"14D_Z[)_.O(J]=^(?_(J2?]=D_G7D5)GC8_\ B_(****1QA11
M10!ZC\,O^0)>?]?/_LHKMZXCX9?\@2\_Z^?_ &45V]4>[A?X,0HHHH.@****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX]S1HK._M_1O^@O8?^!*?XT?V_HW_07L/_ E/\: YX]S1HK._M_1O^@O8?\
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MZ>_XTF<F+H>TC=;H\;HISH\4C1R*5=2596&"".QIM(\4**** "BBB@ HHHH
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MTR'1]+@L8/NQKRV.6;N3]331VX*CSSYWLB[1113/8"BBB@ HHHH *X3XG_\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+6-#%SNN+4
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M4 %%%% 'O^G_ /(-M?\ KBG\A5FJVG_\@VU_ZXI_(59JCZ2.R"BBB@84444
M%%%% !1110 5YEXU\'&U>35--BS;GF:%!_JS_> _N_R^G3TVB@RK48U8\K/G
M>BO1_%7@/S"]]HR ,?FDMAW]T_P_+TKSIT:-V1U*LIPRL,$&I/$JT94I6D-H
MHHH,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "O0/A=_Q\ZE_N1_S:O/Z] ^%W
M_'SJ7^Y'_-J9T83^-$](HHHIGNA1110 4444 <I\0_\ D5)/^NR?SKR*O7?B
M'_R*DG_79/YUY%29XV/_ (OR"BBBD<84444 >H_#+_D"7G_7S_[**[>N(^&7
M_($O/^OG_P!E%=O5'NX7^#$****#H"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\9\=?\ (Y7_ /VS
M_P#1:U[-7C/CK_D<K_\ [9_^BUI,X<P_A+U_S.=HHHI'D!1110 5[-7C->S4
MSMP?VOD>.W'_ !\R_P"^?YU'4EQ_Q\R_[Y_G4=(XGN%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !4D$,MS.D,,;22N=JHHR2:N:3HM_K=SY-E 7Q
M]YSPB?4UZOX;\)V?A^+S.)[UAAYB.GLH[#]33.BAAI57Y$?A'PLF@6AEGVO?
MS#YV'.P?W1_4_P"%=+113/:A",(\L0HHHH+"BBB@ HHHH *X3XG_ /(-L/\
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MY5/7Z!3^!>AF%%%%6 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZM5['&45V?\ P@7_ %$__('_ -E1_P (%_U$_P#R!_\ 94!]6J]CC**[/_A
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M_A O^HG_ .0/_LJ ^K5>QQE%=HO@#<P']I]3C_4?_95J1_"Z$?ZW57;_ '8
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M_"!?]1/_ ,@?_94?\(%_U$__ "!_]E0'U:KV.,KUWX>?\BI'_P!=G_G7*_\
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ME^TN/XK@[OTZ?I70I&D2!(T5$7@*HP!3J*9U1A&"M%6"BBB@H**** "BBB@
MHHHH **** "BBB@ HHHH **** .2\4?\A./_ *XC^;5B5UFLZ7]NO$E\[9B,
M+C;GN??WK._X1[_IZ_\ (?\ ]>OD\;@J\\1.48Z-]T6GH8E%;?\ PCW_ $]?
M^0__ *]'_"/?]/7_ )#_ /KUR_V?B?Y?Q7^8[F)16W_PCW_3U_Y#_P#KT?\
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M5>QQE%=G_P (%_U$_P#R!_\ 94?\(%_U$_\ R!_]E0'U:KV.,HKL_P#A O\
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M7L<9179_\(%_U$__ "!_]E1_P@7_ %$__('_ -E0'U:KV.,HKL_^$"_ZB?\
MY _^RH_X0+_J)_\ D#_[*@/JU7L<9179_P#"!?\ 43_\@?\ V5'_  @7_43_
M /('_P!E0'U:KV.,HKL_^$"_ZB?_ ) _^RH_X0+_ *B?_D#_ .RH#ZM5['&4
M5V?_  @7_43_ /('_P!E1_P@7_43_P#('_V5 ?5JO8XRBNS_ .$"_P"HG_Y
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MZ*[/_A O^HG_ .0/_LJ/^$"_ZB?_ ) _^RI'F?5JO8XRBNS_ .$"_P"HG_Y
M_P#LJ/\ A O^HG_Y _\ LJ ^K5>QQE>S5QG_  @7_43_ /('_P!E7H'V#_IK
-_P".TSKPM&<;W1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gpbisf2hhsz0000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gpbisf2hhsz0000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !O 0\# 2(  A$! Q$!_\0
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M6]7RV.J*IB9R7<^IP%-T\-"+['#?%'QG=>#/#]M<:?Y#7MQ<"-%F4D; I+'
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MPN3ZD_,/R45VVF?'/PK>,J7D=]8-MRS2Q;T!] 4))_[Y%55Q6:TMZ::\KO\
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M)Q=XNP&98^'-#TRX^T6&C:=:38QYD%JB-CTR!FM(J&&& (/8BEHIRE*3O)W
MC\B'_GDG_?(J2BBI **** "BBB@ HHHH **** *]Y8VFHV[6][:P7,#=8YXP
MZG\#Q7,7_P +_!>HR>9+H-O&V,#[.S0@?\!0@?I77T5K3KU:?P2:]&!Y?<?
M?PK*[-%=:I!GHJS(5'YH3^M:O@GX867@G6;G4;?4)[EIH# %D0#:"P8\CK]T
M5W=%;SS#%3@X2FVF.["BBBN,04444 %%%% !7RM\5M8.L?$74V61FAM&%I&"
M,;=G##_OO>?QKZ>U6_32M'O=1D4NEI;R3LHZD*I;'Z5\93O-<W$D\S%Y96+N
MQ/+,3DFOH^'J-ZDZKZ*WW_\ #%1/;/V?]' BU?6WC4DLMI#)GD8^>08_&/\
M*O;*X_X7:2-'^'>DQE4\RXB^U2,O\1D^89]PI4?A785Y695O;8J<O.WW:">X
?4445PB"BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
